Sign in
Stories
China's 2022 NRDL Update: Promising Opportunities for Innovative Drugs
Share
Antithrombotic/Anticoagulant Drugs Marke...
AscellaHealth Forecasts Robust Outlook f...
Asia Pacific Epilepsy Therapeutic Market...
Immuno-Oncology Market Set for Substanti...
Oncology Drugs Market Boom Ahead
Oncology Drugs Market Booms 2030
Overview
API
Trinity Life Sciences reports on China's 2022 NRDL update, highlighting promising pricing and access opportunities for innovative drugs with significant clinical benefit. The update includes improved negotiation success rates, a focus on innovative therapy inclusion, and a growing presence of multinational manufacturers.
Ask a question
How can multinational manufacturers benefit from the growing presence in the NRDL?
How does China's NRDL update impact drug pricing and accessibility?
What are the key factors driving the focus on including innovative therapies in the NRDL?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage